Document is current
Any future updates will be listed below
-
Authors
Jacoby, Jay https://orcid.org/0009-0003-9184-6019
Mahalingam, Deva
Alistar, Angela
Garmey, Edward
Kazmi, Syed
Mooneyham, Teresa
Sun, Lijun
Yap, Timothy A
Vu, Peter
Moser, Justin https://orcid.org/0000-0002-0643-6759
-
Clinical Trials BETA
Clinical trials referenced in this document:
nct04020185 at ClinicalTrials.govnct04420884 at ClinicalTrials.govDocuments that mention this clinical trial
Phase 1 first-in-human dose-escalation study of IMSA101, a novel cyclic di-nucleotide STING agonist, for patients with advanced solid tumor malignancies
https://doi.org/10.1136/jitc-2025-011572
nct05514717 at ClinicalTrials.govDocuments that mention this clinical trial
Constructing the cure: engineering the next wave of antibody and cellular immune therapies
https://doi.org/10.1136/jitc-2025-011761
778 Phase 1b study of dazostinag plus pembrolizumab after hypofractionated radiotherapy in patients with non-small-cell lung cancer, triple-negative breast cancer, or head and neck squamous-cell carcinoma
https://doi.org/10.1136/jitc-2024-sitc2024.0778
Phase 1 first-in-human dose-escalation study of IMSA101, a novel cyclic di-nucleotide STING agonist, for patients with advanced solid tumor malignancies
https://doi.org/10.1136/jitc-2025-011572
1022 Evaluating the mechanism of enhanced responses to the IV STING agonist dazostinag (TAK-676) plus pembrolizumab in neuroendocrine tumors
https://doi.org/10.1136/jitc-2024-sitc2024.1022
Reversible downregulation of HLA class I in adenoid cystic carcinoma
https://doi.org/10.1136/jitc-2024-011380
nct05471856 at ClinicalTrials.govDocuments that mention this clinical trial
Constructing the cure: engineering the next wave of antibody and cellular immune therapies
https://doi.org/10.1136/jitc-2025-011761
Phase 1 first-in-human dose-escalation study of IMSA101, a novel cyclic di-nucleotide STING agonist, for patients with advanced solid tumor malignancies
https://doi.org/10.1136/jitc-2025-011572
654 XMT-2056: a phase 1 study of a HER2-directed STING agonist antibody drug conjugate (ADC) in HER2+ solid tumors
https://doi.org/10.1136/jitc-2024-sitc2024.0654
Where does ISAC (immune-stimulating antibody conjugates) go from here?
https://doi.org/10.1136/jitc-2025-012500
1053 XMT-2056, a HER2-targeted immunosynthen STING agonist antibody-drug conjugate, induces anti-tumor activity at low doses in preclinical models
https://doi.org/10.1136/jitc-2024-sitc2024.1053
nct06021626 at ClinicalTrials.govDocuments that mention this clinical trial
Phase 1 first-in-human dose-escalation study of IMSA101, a novel cyclic di-nucleotide STING agonist, for patients with advanced solid tumor malignancies
https://doi.org/10.1136/jitc-2025-011572
nct06626633 at ClinicalTrials.govDocuments that mention this clinical trial
Phase I trial of CRD3874-SI, a systemically administered STING agonist, in patients with advanced solid tumors.
https://doi.org/10.1200/jco.2024.42.16_suppl.tps2690
Phase 1 first-in-human dose-escalation study of IMSA101, a novel cyclic di-nucleotide STING agonist, for patients with advanced solid tumor malignancies
https://doi.org/10.1136/jitc-2025-011572
P01.09 CRD3874-SI: a novel allosteric STING agonist with high systemic tolerability
https://doi.org/10.1136/jitc-2024-itoc10.19
782-D Systemic delivery of novel, allosteric STING agonist CRD3874-SI leads to robust anti-cancer activity by generating pro-inflammatory Type I IFN signals while blocking proton channel mediated toxicity
https://doi.org/10.1136/jitc-2023-sitc2023.0782-d
Documents that mention this clinical trial
Phase 1 first-in-human dose-escalation study of IMSA101, a novel cyclic di-nucleotide STING agonist, for patients with advanced solid tumor malignancies
https://doi.org/10.1136/jitc-2025-011572
-
Funding
Funding for this research was provided by:
ImmuneSensor Therapeutics (N/A)
- License Information
